

Laboratory Services


Analytical Techniques


Accreditation
Laboratory & Science
Well Ensure you always get best results.
We have developed search strategies for leading brands to small and medium sized laboratory’s across many industries in the UK and worldwide. We are an experienced and talented team.
Chemical Research
Environmental Testing
Anatomical Pathology
Chemical Research
High quality Services
Medical Professionals:
Who's in the Laboratory



To help stakeholders in government and business make smart decisions.





325 +
Finished Projects
460 +
Professional Staff
640 +
Our Suppliers
725 +
Lab Technicians
Testimonials
What Clients Say
Long established fact that a reader will be distracted by the readable content of a page when looking at it's layout. The point of using Lorem Ipsum

Victoria Porter
CEO at Google INCLong established fact that a reader will be distracted by the readable content of a page when looking at it's layout. The point of using Lorem Ipsum

Maria Flynn
CEO at Google INCLong established fact that a reader will be distracted by the readable content of a page when looking at it's layout. The point of using Lorem Ipsum

Gina Kennedy
CEO at Google INCLaboratory Questions
Work Together to Create
Laboratories used for scientific research take many forms because of the differing requirements of specialists in the various fields of science and engineering with laboratory.
Laboratories used for scientific research take many forms because of the differing requirements of specialists in the various fields of science and engineering with laboratory.
Laboratories used for scientific research take many forms because of the differing requirements of specialists in the various fields of science and engineering with laboratory.
Please Fill A Form
Laboratory & Skills
We Are Here for you Make an Appointment
We have developed strategies for major brands to all the sized laboratory’s across many industries. We are an experienced and talented team member.
Biotechnology
Medical Research
Vaccines






Laboratory Blog
Read Our Latest News
We offer a laboratory technology to reward clients and suppliers via cashback, rebates and discounts. Right now the lab technologies are the upgraded.
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine
KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.
"We are pleased to announce the addition of these patents as we continue to execute on our strategy to broaden Lexaria's patent portfolio. We believe that this not only increases our likelihood of entering into commercial deals within the pharmaceutical industry, but that it also serves as an important building block for establishing and protecting long-term value for our shareholders and all stakeholders," said Rich Christopher, CEO of Lexaria. "The achievement of 50 worldwide patents marks the accomplishment of a milestone that had been envisioned by the Company's management for over a decade."
Lexaria has been granted a new patent in Australia within its patent family #24, Compositions and Methods for Treating Epilepsy. This broadens Lexaria's intellectual property protection for the use of its DehydraTECH™ enhanced processing technology related to the treatment of epilepsy outside of the USA, where a strong patent portfolio of 6 existing patents has already been built. This new patent will expire in 2044.
Lexaria has also been granted a new patent in Japan within its patent family #20, Compositions and Methods for Sublingual Delivery of Nicotine. This patent joins already-existing patents within the same family in both the USA and Canada. This new patent will expire in 2043.
The epilepsy drug market was US$9.5 billion in 2023 and is expected to reach sales of over $15 billion by 2032. Approximately 50 million people in the US alone are affected by epilepsy.
The global retail oral nicotine market was valued at US$5.5 billion in 2023 and is expected to grow at 26%/yr until at least 2030, with additional revenue generated within the medically-prescribed market. The nicotine pouch market alone - where DehydraTECH™ has demonstrated absorption benefits in earlier studies - is expected to reach US$25.4 billion in revenue by 2030. Altria Ventures Inc. the 16.67% shareholder of Lexaria Nicotine LLC, holds a non-exclusive license to the use of DehydraTECH with nicotine products.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda®)
Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide
KELOWNA, BC / ACCESS Newswire / June 11, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that human study GLP-1-H25-5 (the "Study") which compared oral capsules of DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide has been successfully completed with partial results now available.
In distinct clinical human studies, Lexaria has now demonstrated clear reductions in AEs utilizing oral DehydraTECH versions of all three of the major GLP-1 drugs sold in the world today: liraglutide, semaglutide, and tirzepatide. For liraglutide specifically, which is currently sold in genericized versions due to patent expiration, Lexaria is now searching for a pharmaceutical partner interested in utilizing DehydraTECH to support an FDA-registered oral alternative to the current injectable brands within GLP-1.
There were a total of 23 AEs in the Saxenda® injected liraglutide study arm, as compared to 21 in DehydraTECH-liraglutide oral capsule arm. Of note, 4 of the AEs in the DehydraTECH-liraglutide oral capsule study arm were due to the placement of the peripheral intravenous line used for blood sampling necessary for purposes of conducting the study and, thus, unrelated to the drug treatment; whereas only 1 such AE was recorded in the Saxenda® injected liraglutide study arm. With those AEs removed from the analysis, oral DehydraTECH-liraglutide offered a 22.7% reduction in AEs as compared to the injected Saxenda®.
Particularly noteworthy were the reductions by 67% with respect to nausea and by 31% with respect to gastrointestinal AEs, utilizing oral DehydraTECH-liraglutide as compared to the injected Saxenda®.
The differences in measurements of blood glucose, insulin and body weight across most time points were not statistically significantly different, with remarkable similarity in many areas and slight differences in others. Weight loss was experienced by 9 out of 10 people in each Study arm and slightly higher in the Saxenda® study arm; though weight loss was not a primary goal of this study with the relatively short treatment period. Evaluating the safety and tolerability of the DehydraTECH-liraglutide capsules relative to Saxenda® was the primary endpoint of this Study and this objective was successfully met with clear signs of improvement.
The two most important strategic objectives of this Study were:
1 - To discover whether DehydraTECH processing of liraglutide would work sufficient to potentially allow for an oral version of the drug to be compared to the current injection-only delivery method; and
2 - To demonstrate comparable functional results to the injected version, which if successful, could allow for an expedited FDA regulatory pathway known as a 505(b)(2) application that is available when an alternate version of a drug (e.g., the dosage form change from injection to oral administration as tested within this Study) retains certain similar performance characteristics as an earlier-approved version of that same drug.
In both these respects, Lexaria feels that the partially completed results from this Study have shown tremendous promise, while also evidencing tolerability advantages from a user appeal perspective.
Saxenda® is owned by Novo Nordisk, who also sells an oral tablet form of the blockbuster GLP-1 drug semaglutide under the brand name Rybelsus®. Of note, the salcaprozate sodium ("SNAC") delivery technology that Novo Nordisk acquired for $1.8 billion utilized within the Rybelsus® tablet ("SNAC") was found by other researchers to be unfavourable for co-formulation of an oral version of liraglutide.
For these reasons, Lexaria is excited about the possibility of establishing DehydraTECH-liraglutide as a brand new oral liraglutide-dosing alternative to Saxenda® and the other generic versions of injected liraglutide. Lexaria feels this is an unmet market need which DehydraTECH may empower.
Background
On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which demonstrated positive findings supportive of advancement to the human clinical Study described herein.
Lexaria has previously shown in other GLP-1 studies in humans, that certain oral DehydraTECH formulations demonstrated superior effectiveness and bloodstream delivery, as well as reduced AEs as compared to the oral semaglutide and injectable tirzepatide products on the market today.
Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk. Despite the launch of a genericized version of liraglutide by Teva Pharmaceutical Industries, Ltd. in June of 2024, Novo Nordisk generated US$1.0 billion in Saxenda® revenue, as well as an additional US$0.8 billion in Victoza® revenue during 2024.
About the Study
Study GLP-1-H25-5 was a pilot, cross-over investigation in 10 overweight (average weight 73 Kg, average body mass index 26.81) volunteers. Saxenda® injection was administered daily at its commercially available starting dose of 0.6 mg for 7 days with a follow-up evaluation at day 8, compared to oral DehydraTECH-liraglutide (45 mg) also administered daily for 7 days with an identical day 8 evaluation. All drug administrations were performed after an overnight fast. Oral administration was accomplished with a 50 mL glass of water. Blood draws were performed upon the subjects at baseline (pre-dose) and multiple time points over the first 12 hours of day 1 of the Study, followed by daily draws 30-minutes post-dosing on each of days 2-7 of the Study and, finally, on day 8 without any dosing. Subjects were allowed to consume standardized meals/snacks over the 12 hours post-dosing on the first treatment day at predetermined time intervals. Subjects were allowed to resume their normal diet following fasted dosing on the subsequent treatment days.
The DehydraTECH-liraglutide 45 mg dose equated to a 75-fold multiple of the 0.6 mg Saxenda® liraglutide dose exposure tested. This dosing multiple was selected conservatively relative to the 98 to 196-fold dosing multiple currently used with Novo Nordisk's Rybelsus® branded semaglutide, the only oral GLP-1 drug on the market today, whereby a 14 mg Rybelsus® daily dose is considered to be bioequivalent to a 0.5-1.0 mg once-weekly dose of their Ozempic® or Wegovy® branded semaglutide injectable products. Accordingly, Lexaria notes that there is arguably room to further titrate the DehydraTECH-liraglutide oral dose upwards in prospective future studies, in an effort to most closely match the effectiveness of the injectable regimen consistent with its 505(b)2 application regulatory strategy.
The primary endpoint of the Study was evaluation of the safety and tolerability. Secondary and exploratory objectives included evaluations of pharmacokinetics ("PK") and pharmacodynamic parameters including effects upon body weight, blood glucose and blood insulin levels. Results from the PK component of the Study are still being analyzed and will be reported upon once available.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
Biotechnology Sector's Premier Strategic Partnering Event
KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention ("BIO") in Boston, June 16-19.
With over 1,500 exhibitors and 20,000 attendees, BIO is the largest biotechnology convention in the world. The convention provides a unique forum for networking and exploring collaborations. By participating in BIO 2025, Lexaria is seeking to advance discussions with prospective partners and strategic investors, to support the development of its clinical stage DehydraTECH® enhanced emerging drug product candidates.
Lexaria is arranging a full slate of 1-on-1 meetings with global and regional corporate leaders in the fields of weight loss, diabetes and hypertension, among others. Lexaria has a limited number of meeting times still available. Interested parties are encouraged to reach out to the Company directly or via the BIO Partnering TM platform to request a meeting at BIO.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire